{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T13:16:01Z","timestamp":1770556561713,"version":"3.49.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2025.103065","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:46:45Z","timestamp":1765180005000},"page":"103065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recommendations on the management of kinase inhibitor-associated hyperlipidemia in patients with lung cancer"],"prefix":"10.1016","volume":"143","author":[{"given":"Hung-Ju","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Gin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Hao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103065_b0005","unstructured":"World Cancer Research Fund International. Lung cancer statistics. [Accessed 5 January 2025]; Available from: https:\/\/www.wcrf.org\/cancer-trends\/lung-cancer-statistics\/."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103065_b0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000442147","article-title":"A phase I trial of temsirolimus and pemetrexed in patients with advanced non-small cell lung cancer","volume":"61","author":"Waqar","year":"2016","journal-title":"Chemotherapy"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103065_b0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jtho.2015.11.001","article-title":"Positive interaction between prophylactic cranial irradiation and maintenance sunitinib for untreated extensive-stage small cell lung cancer patients after standard chemotherapy: a secondary analysis of CALGB 30504 (ALLIANCE)","volume":"11","author":"Salama","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103065_b0020","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/JTO.0000000000000693","volume":"10","author":"Paz-Ares","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103065_b0025","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-14-1998","article-title":"A translational, pharmacodynamic, and pharmacokinetic phase IB clinical study of everolimus in resectable non\u2013small cell lung cancer","volume":"21","author":"Owonikoko","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103065_b0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103065_b0035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103065_b0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103065_b0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103065_b0050","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2025.103065_b0055","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/CIRCULATIONAHA.118.034273","article-title":"Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease","volume":"138","author":"Abdullah","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103065_b0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12889-021-10429-0","article-title":"Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from Global Burden of Disease Study 2017","volume":"21","author":"Amini","year":"2021","journal-title":"BMC Public Health"},{"issue":"9 Suppl","key":"10.1016\/j.ctrv.2025.103065_b0065","first-page":"S139","article-title":"Epidemiology and management of hyperlipidemia","volume":"23","author":"Karr","year":"2017","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103065_b0070","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00041433-199408000-00003","article-title":"The mouse as a model for human cardiovascular disease and hyperlipidemia","volume":"5","author":"Paigen","year":"1994","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103065_b0075","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.jfma.2022.05.010","article-title":"2022 Taiwan lipid guidelines for primary prevention","volume":"121","author":"Huang","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103065_b0080","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103065_b0085","first-page":"555","article-title":"Chinese expert consensus on management of special adverse effects associated with lorlatinib","volume":"25","author":"Zhou","year":"2022","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103065_b0090","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103065_b0095","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jfma.2022.03.001","article-title":"2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: coronary artery disease, peripheral artery disease and ischemic stroke","volume":"121","author":"Chen","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103065_b0100","first-page":"4","article-title":"2023 guidelines of the Taiwan Society of Cardiology on the diagnosis and management of chronic coronary syndrome","volume":"39","author":"Ueng","year":"2023","journal-title":"Acta Cardiol Sin"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103065_b0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ctrv.2025.103065_b0110","unstructured":"Bragalone DL, Minich SS, eds. Drug Information Handbook for Oncology. 17th ed. Hudson, Ohio, OH: Lexi- Comp, Inc.; 2022."},{"key":"10.1016\/j.ctrv.2025.103065_b0115","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. [Accessed 18 August 2025]; Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"10.1016\/j.ctrv.2025.103065_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112391","article-title":"Targeting mTOR for fighting diseases: a revisited review of mTOR inhibitors","volume":"199","author":"Xu","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103065_b0125","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/j.cllc.2018.03.016","article-title":"A placebo-controlled phase II study of ruxolitinib in combination with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer and systemic inflammation","volume":"19","author":"Giaccone","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103065_b0130","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","article-title":"Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I","volume":"15","author":"Mesa","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"10.1016\/j.ctrv.2025.103065_b0135","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103065_b0140","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1111\/cas.15888","article-title":"Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: final results of the phase 2 J-ALTA trial","volume":"114","author":"Yoshida","year":"2023","journal-title":"Cancer Sci"},{"issue":"21","key":"10.1016\/j.ctrv.2025.103065_b0145","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103065_b0150","unstructured":"US Food and Drug Administration. Highlights of prescribing information-Lorbrena\u00ae (lorlatinib) tablets, for oral use, 2018. [Accessed 1 Feb 2025]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210868s000lbl.pdf."},{"issue":"12","key":"10.1016\/j.ctrv.2025.103065_b0155","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103065_b0160","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1177\/10781552211004698","article-title":"A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy","volume":"27","author":"McGee","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103065_b0165","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3390\/ijms25105489","article-title":"Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives","volume":"25","author":"Li","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103065_b0170","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jtho.2017.01.022","article-title":"Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB\/IV non-small cell lung cancer: arandomized, double-blind, placebo-controlled phase III study-CALGB 30607 (ALLIANCE)","volume":"12","author":"Baggstrom","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103065_b0175","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/bjc.2017.137","article-title":"Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group","volume":"117","author":"Koinis","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103065_b0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12020-023-03362-2","article-title":"Metabolic adverse events of multitarget kinase inhibitors: a systematic review","volume":"81","author":"Acitelli","year":"2023","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103065_b0185","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103065_b0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/curroncol28010029","article-title":"Evaluation and management of dyslipidemia in patients treated with lorlatinib","volume":"28","author":"Blais","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2025.103065_b0195","doi-asserted-by":"crossref","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3415-537. Doi: 10.1093\/eurheartj\/ehae177.","DOI":"10.1093\/eurheartj\/ehae177"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103065_b0200","first-page":"479","article-title":"2024 guidelines of the Taiwan Society of Cardiology on the primary prevention of atherosclerotic cardiovascular disease\u2013-Part I","volume":"40","author":"Chao","year":"2024","journal-title":"Acta Cardiol Sin"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103065_b0205","first-page":"669","article-title":"2024 guidelines of the Taiwan Society of Cardiology on the primary prevention of atherosclerotic cardiovascular disease\u2013-Part II","volume":"40","author":"Chao","year":"2024","journal-title":"Acta Cardiol Sin"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103065_b0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3949\/ccjm.87a.19078","article-title":"ACC\/AHA lipid guidelines: personalized care to prevent cardiovascular disease","volume":"87","author":"Reiter-Brennan","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.ctrv.2025.103065_b0215","unstructured":"L\u00f3pez-Fernandez T, Dent SF. European Society of Cardiology. Strategies for risk stratification and cardiovascular toxicity prevention in patients with cancer. [Accessed 21 February 2025]; Available from: https:\/\/www.escardio.org\/Councils\/Council-for-Cardiology-Practice-(CCP)\/Cardiopractice\/strategies-for-risk-stratification-and-cardiovascular-toxicity-prevention-in-pat."},{"issue":"14_suppl","key":"10.1016\/j.ctrv.2025.103065_b0220","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1200\/jco.2004.22.90140.6098","article-title":"The NCI Common Terminology Criteria for adverse events (CTCAE) v 3.0 is the new standard for oncology clinical trials","volume":"22","author":"Colevas","year":"2004","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2025.103065_b0225","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103065_b0230","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jfma.2016.11.013","article-title":"2017 Taiwan lipid guidelines for high risk patients","volume":"116","author":"Li","year":"2017","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103065_b0235","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103065_b0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2217\/fon.14.136","article-title":"Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis","volume":"11","author":"Abdel-Rahman","year":"2015","journal-title":"Future Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103065_b0245","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103065_b0250","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1634\/theoncologist.2015-0065","article-title":"The prevalence and impact of hyperglycemia and hyperlipidemia in patients with advanced cancer receiving combination treatment with the mammalian target of rapamycin inhibitor temsirolimus and insulin growth factor-receptor antibody cixutumumab","volume":"20","author":"Busaidy","year":"2015","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103065_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100779","article-title":"Risk of dyslipidemia associated with VEGF\/VEGFR inhibitors: a meta-analysis","volume":"13","author":"Dai","year":"2020","journal-title":"Transl Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103065_b0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120427","article-title":"The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?","volume":"10","author":"Pantano","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103065_b0265","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/JTO.0b013e318282709c","article-title":"Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer","volume":"8","author":"Ramalingam","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103065_b0270","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.clgc.2014.08.009","article-title":"Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?","volume":"13","author":"Tassi","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103065_b0275","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ajco.12473","article-title":"A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma","volume":"12","author":"Song","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103065_b0280","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103065_b0285","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103065_b0290","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/00498254.2015.1109160","article-title":"The drug\u2013drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4","volume":"46","author":"Wang","year":"2016","journal-title":"Xenobiotica"},{"issue":"Suppl 10","key":"10.1016\/j.ctrv.2025.103065_b0295","article-title":"Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity","volume":"6","author":"Mikus","year":"2017","journal-title":"Transl Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103065_b0300","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1517\/17425255.2015.1056149","article-title":"Drug\u2013drug interactions that interfere with statin metabolism","volume":"11","author":"Hirota","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ctrv.2025.103065_b0305","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2147\/DDDT.S249098","article-title":"Pharmacokinetic-based drug\u2013drug interactions with anaplastic lymphoma kinase inhibitors: a review","volume":"14","author":"Zhao","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103065_b0310","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40262-023-01309-4","article-title":"Evaluation of the effect of lorlatinib on CYP2B6, CYP2C9, UGT, and P-glycoprotein substrates in patients with advanced non-small cell lung cancer","volume":"63","author":"Chen","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ctrv.2025.103065_b0315","unstructured":"Taiwan Food and Drug Administration. Lorviqua film coated tablets 25mg; 2019. [Accessed 15 January 2025]; Available from: https:\/\/www.fda.gov.tw\/tc\/includes\/GetFile.ashx?mid=189&id=34933&t=s."},{"issue":"4","key":"10.1016\/j.ctrv.2025.103065_b0320","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12031-017-0897-x","article-title":"Inhibition of mTOR pathway by rapamycin decreases P-glycoprotein expression and spontaneous seizures in pharmacoresistant epilepsy","volume":"61","author":"Chi","year":"2017","journal-title":"J Mol Neurosci"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103065_b0325","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","article-title":"Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia","volume":"18","author":"Peer","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103065_b0330","article-title":"Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions","volume":"34","author":"Umehara","year":"2019","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.ctrv.2025.103065_b0335","unstructured":"UpToDate. Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer. [Accessed 18 Aug 2025]; Available from: https:\/\/www.uptodate.com\/contents\/anaplastic-lymphoma-kinase-alk-positive-advanced-non-small-cell-lung-cancer."},{"key":"10.1016\/j.ctrv.2025.103065_b0340","unstructured":"Merative Micromedex. [Accessed 18 August 2025]; Available from: https:\/\/www.micromedexsolutions.com\/."},{"key":"10.1016\/j.ctrv.2025.103065_b0345","unstructured":"Drugs.com. Drug interactions checker. [Accessed 15 January 2025]; Available from: https:\/\/www.drugs.com\/interactions-check.php?drug_list=3974-0,2067-0."},{"issue":"2","key":"10.1016\/j.ctrv.2025.103065_b0350","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/CIRCULATIONAHA.106.621417","article-title":"Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications","volume":"114","author":"Chiuve","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103065_b0355","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103065_b0360","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM200007063430103","article-title":"Primary prevention of coronary heart disease in women through diet and lifestyle","volume":"343","author":"Stampfer","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103065_b0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251189","article-title":"The healthy Taiwanese eating approach is inversely associated with all-cause and cause-specific mortality: a prospective study on the nutrition and health survey in Taiwan, 1993-1996","volume":"16","author":"Chuang","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103065_b0370","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/nu12020334","article-title":"Defining a healthy diet: evidence for the role of contemporary dietary patterns in health and disease","volume":"12","author":"Cena","year":"2020","journal-title":"Nutrients"},{"issue":"14","key":"10.1016\/j.ctrv.2025.103065_b0375","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103065_b0380","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jama.2017.0947","article-title":"Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States","volume":"317","author":"Micha","year":"2017","journal-title":"J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103065_b0385","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamainternmed.2016.4182","article-title":"Association of animal and plant protein intake with all-cause and cause-specific mortality","volume":"176","author":"Song","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103065_b0390","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/nu10020143","article-title":"Association of dietary patterns with components of metabolic syndrome and inflammation among middle-aged and older adults with metabolic syndrome in Taiwan","volume":"10","author":"Syauqy","year":"2018","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103065_b0395","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/clc.4960271008","article-title":"A low-carbohydrate diet in overweight patients undergoing stable statin therapy raises high-density lipoprotein and lowers triglycerides substantially","volume":"27","author":"Gann","year":"2004","journal-title":"Clin Cardiol"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103065_b0400","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1200\/JCO.22.00687","article-title":"Exercise, diet, and weight management during cancer treatment: ASCO guideline","volume":"40","author":"Ligibel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103065_b0405","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s11912-022-01309-w","article-title":"Cardiovascular disease in adult cancer survivors: a review of current evidence, strategies for prevention and management, and future directions for cardio-oncology","volume":"24","author":"Muhandiramge","year":"2022","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103065_b0410","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.117.024671","article-title":"Exercise therapy and cardiovascular toxicity in cancer","volume":"137","author":"Scott","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103065_b0415","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio\u2010oncology service in the United Kingdom\u2014a five\u2010year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103065_b0420","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/ehf2.12840","article-title":"The impact of a multidisciplinary cardio-oncology programme on cardiovascular outcomes in Taiwan","volume":"7","author":"Chang","year":"2020","journal-title":"ESC Heart Fail"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:56:12Z","timestamp":1770479772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":84,"alternative-id":["S0305737225001872"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103065","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations on the management of kinase inhibitor-associated hyperlipidemia in patients with lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103065"}}